Biological Trace Element Research

, Volume 137, Issue 1, pp 96–109 | Cite as

The Defensive Effect of Benfotiamine in Sodium Arsenite-Induced Experimental Vascular Endothelial Dysfunction

Article
First Online:
Received:
Accepted:

Abstract

The present study has been designed to investigate the effect of benfotiamine, a thiamine derivative, in sodium arsenite-induced vascular endothelial dysfunction (VED) in rats. Sodium arsenite (1.5 mg−1 kg−1 day−1 i.p., 2 weeks) was administered in rats to produce VED. The development of VED was assessed by employing isolated aortic ring preparation and estimating the serum and aortic concentrations of nitrite/nitrate. Further, the integrity of vascular endothelium in thoracic aorta was assessed by scanning electron microscopy. Moreover, the oxidative stress was assessed by estimating serum thiobarbituric acid reactive substances (TBARS) and aortic superoxide anion generation. The administration of sodium arsenite markedly produced VED by attenuating acetylcholine-induced endothelium-dependent relaxation, decreasing serum and aortic concentrations of nitrite/nitrate, and impairing the integrity of vascular endothelium. Further, sodium arsenite produced oxidative stress by increasing serum TBARS and aortic superoxide generation. The treatment with benfotiamine (25, 50, and 100 mg−1 kg−1 day−1 p.o.) or atorvastatin (30 mg−1 kg−1 day−1 p.o., a standard agent) prevented sodium arsenite-induced VED and oxidative stress. However, the beneficial effects of benfotiamine in preventing the sodium arsenite-induced VED were attenuated by co-administration with N-omega-nitro-l-arginine methyl ester (L-NAME) (25 mg−1 kg−1 day−1, i.p.), an inhibitor of NOS. Thus, it may be concluded that benfotiamine reduces oxidative stress and activates endothelial nitric oxide synthase to enhance the generation and bioavailability of NO and subsequently improves the integrity of vascular endothelium to prevent sodium arsenite-induced experimental VED.

Keywords

Sodium arsenite Endothelial dysfunction Benfotiamine eNOS 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

We express our gratitude to Shri. Parveen Garg Ji, Honorable Chairman, ISF College of Pharmacy, Moga, Punjab, India for his inspiration and constant support for this study.

References

  1. 1.
    Le Brocq M, Leslie JS, Milliken P, Megson IL (2008) Endothelial dysfunction: from molecular mechanism to measurements, clinical implications and therapeutic opportunities. Antioxid Redox Signal 10:1631–1674CrossRefPubMedGoogle Scholar
  2. 2.
    Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA (2006) Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 5:4CrossRefPubMedGoogle Scholar
  3. 3.
    Balakumar P, Jindal S, Shah DI, Singh M (2007) Experimental models for vascular endothelial dysfunction. Trends Med Res 2:12–20CrossRefGoogle Scholar
  4. 4.
    Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373–376CrossRefPubMedGoogle Scholar
  5. 5.
    Ignarro LJ (1989) Endothelium-derived nitric oxide, actions and properties. FASEB J 3:31–36PubMedGoogle Scholar
  6. 6.
    Balakumar P, Kaur T, Singh M (2008) Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 245:49–64CrossRefPubMedGoogle Scholar
  7. 7.
    Desjardins F, Balligand JL (2006) Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg 61:326–334PubMedGoogle Scholar
  8. 8.
    Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Bio 23:168–175CrossRefGoogle Scholar
  9. 9.
    Balakumar P, Koladiya RU, Ramasamy S, Rathinavel A, Singh M (2008) Pharmacological interventions to prevent vascular endothelial dysfunction: future directions. J Health Sci 54:1–16CrossRefGoogle Scholar
  10. 10.
    Yang Z, Ming XF (2006) Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 4:53–56CrossRefPubMedGoogle Scholar
  11. 11.
    Giansante C, Fiotti N (2006) Insights into human hypertension: the role of endothelial dysfunction. J Human Hypertens 20:725–726CrossRefGoogle Scholar
  12. 12.
    Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel M (2001) Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673–2678CrossRefPubMedGoogle Scholar
  13. 13.
    Engel RR, Rich CH, Receveur O, Smith AH (1994) Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184–209PubMedGoogle Scholar
  14. 14.
    Wu MM, Chiou HY, Ho IC, Chen CJ, Lee TC (2003) Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect 111:1429–1438PubMedGoogle Scholar
  15. 15.
    Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR et al (1999) Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 159:65–75CrossRefPubMedGoogle Scholar
  16. 16.
    Bunderson M, Coffin JD, Beall HD (2004) Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol 201:32–39CrossRefPubMedGoogle Scholar
  17. 17.
    Tsou TC, Tsai FY, Hsieh YW, Li LA, Yen SC, Chang LW (2005) Arsenic induces cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol Appl Pharmacol 208:277–284CrossRefPubMedGoogle Scholar
  18. 18.
    Lynn S, Gurr JR, Lai HT, Jan KY (2000) NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 86:514–519PubMedGoogle Scholar
  19. 19.
    Smith KR, Klei LR, Barchowsky A (2001) Arsenite stimulates plasma membrane NAD(P)H oxidase in vascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 280:442–449Google Scholar
  20. 20.
    Balakumar P, Jindal S, Singh M (2007) Novel use of uric acid and sodium arsenite to induce vascular endothelial dysfunction. J Pharmacol Toxicol 2:437–446CrossRefGoogle Scholar
  21. 21.
    Jindal S, Singh M, Balakumar P (2008) Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol 128:383–391CrossRefPubMedGoogle Scholar
  22. 22.
    Berrone E, Beltramo E, Solimine C (2006) Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cell cultured in high glucose. J Biol Chem 281:9307–9313CrossRefPubMedGoogle Scholar
  23. 23.
    Wu S, Ren J (2006) Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-α. Neurosci Lett 394:158–162CrossRefPubMedGoogle Scholar
  24. 24.
    Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt dependent phosphorylation. Nature 399:601–605CrossRefPubMedGoogle Scholar
  25. 25.
    Shah DI, Singh M (2007) Possible role of Akt to improve vascular endothelial dysfunction in diabetic and hyperhomocysteinemic rats. Mol Cell Biochem 295:65–74CrossRefPubMedGoogle Scholar
  26. 26.
    Shah DI, Singh M (2007) Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction. Int J Cardiol 120:317–324CrossRefPubMedGoogle Scholar
  27. 27.
    Marchetti V, Menghinni R, Rizza S, Vivanti A, Feccia T, Lauro D, Fukamizu A, Lauro R, Federici1 M (2006) Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FOXO signaling. Diabetes 55:2231–2237Google Scholar
  28. 28.
    Gadau S, Emanueli C, Linthout SV, Graiani G, Todaro M, Meloni M, Campesi I, Invernici G, Spillmann F, Ward K, Madeddu P (2006) Benfotaimine accelerate the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49:405–420CrossRefPubMedGoogle Scholar
  29. 29.
    Balakumar P, Sharma R, Singh M (2008) Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in rats. Pharmacol Res 58:356–363CrossRefPubMedGoogle Scholar
  30. 30.
    Mittra S, Singh M (1998) Possible mechanism of captopril induced endothelium-dependent relaxation in isolated rabbit aorta. Mol Cell Biochem 183:63–67CrossRefPubMedGoogle Scholar
  31. 31.
    Shah DI, Singh M (2006) Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats. Fundam Clin Pharmacol 20:595–604CrossRefPubMedGoogle Scholar
  32. 32.
    Malczak HT, Buck RC (1997) Regeneration of endothelium in rat aorta after local freezing. Am J Pathol 86:133–148Google Scholar
  33. 33.
    Lai JCK, Tranfield EM, Walker DC, Dyck J, Kerjner A, Loo S, Wong D, McDonald PC, Moghadasian MH, Janet EW, McManus BM (2003) Ultra structural evidence of early endothelial damage in coronary arteries of rat cardiac allografts. J Heart Lung Transplant 22:993–1004CrossRefPubMedGoogle Scholar
  34. 34.
    Sastry KV, Moudgal RP, Mohan J, Tyagu JS, Rao GS (2002) Spectrophotometric determination of serum nitrite and nitrate by copper–cadmium alloy. Annal Biochem 306:79–82CrossRefGoogle Scholar
  35. 35.
    Ibrahim MA, Asai H, Satoh S, Satoh N, Ueda S (2004) Effect of zaprinast on nitric oxide levels in serum and aortic tissue. Meth Find Exp Clin Pharmacol 26:19–24CrossRefGoogle Scholar
  36. 36.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  37. 37.
    Ma FX, Liu LY, Xiong XM (2003) Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin 24:1027–1032PubMedGoogle Scholar
  38. 38.
    Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT (1998) Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82:810–818PubMedGoogle Scholar
  39. 39.
    States JC, Srivastava S, Chen Y, Barchowsky A (2008) Arsenic and cardiovascular diseases. Toxicol Sci 107:312–323CrossRefPubMedGoogle Scholar
  40. 40.
    Kumagai Y, Pi J (2004) Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 198:450–457CrossRefPubMedGoogle Scholar
  41. 41.
    Pennathur S, Heinecke JW (2007) Oxidative stress and endothelial dysfunction in vascular disease. Curr Diabetes Rep 10:257–264CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Sanjali Verma
    • 1
  • Krishna Reddy
    • 1
  • Pitchai Balakumar
    • 1
  1. 1.Cardiovascular Pharmacology DivisionISF College of PharmacyMogaIndia

Personalised recommendations